Papadopoulos Stelios is a director of Exelixis Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Regulus Therapeutics Inc.
15 Mar 24
4
Regulus Therapeutics Inc.
14 Aug 23
4
Regulus Therapeutics Inc.
13 Jun 23
4
EXELIXIS, INC.
2 Jun 23
4
Regulus Therapeutics Inc.
14 Apr 23
4
BIOGEN INC.
17 Jun 22
4
Regulus Therapeutics Inc.
10 Jun 22
4
EXELIXIS, INC.
27 May 22
4
EXELIXIS, INC.
24 Feb 22
4
Regulus Therapeutics Inc.
1 Dec 21
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | RGLS Regulus Therapeutics | Common Stock | Grant | Acquire A | No | No | 1.6 | 250,000 | 400.00 k | 978,388 |
10 Aug 23 | RGLS Regulus Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 1.36 | 15,000 | 20.40 k | 15,000 |
13 Jun 23 | RGLS Regulus Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 1.45 | 30,000 | 43.50 k | 30,000 |
1 Jun 23 | EXEL Exelixis | Common Stock | Grant | Acquire A | No | No | 0 | 20,718 | 0.00 | 1,260,329 |
13 Apr 23 | RGLS Regulus Therapeutics | Common Stock | Grant | Acquire A | No | No | 0.9001 | 222,198 | 200.00 k | 728,388 |